The current consensus was published in December 2020 in Nature Reviews (Nephrology). It was developed by the ADQI expert group, which included: Mitra K. Nadim, Lui G. Forni, Ravindra L. Mehta, Michael J. Connor Jr, Kathleen D. Liu, Marlies Ostermann, Thomas Rimmele, Alexander Zarbock, Samira Bell, Azra Bihorac, Vincenzo Cantaluppi, Eric Hoste, Faeq Husain-Syed, Michael J. Germain, Stuart L. Goldstein, Shruti Gupta, Michael Joannidis, Kianoush Kashani, Jay L. Koyner, Matthieu Legrand, Nuttha Lumlertgul, Sumit Mohan, Neesh Pannu, Zhiyong Peng, Xose L. Perez-Fernandez, Peter Pickkers, John Prowle, Thiago Reis, Nattachai Srisawat, Ashita Tolwani, Anitha Vijayan, Gianluca Villa, Li Yang, Claudio Ronco and John A. Kellum.
It provides clinical guidelines for the diagnosis, prevention and treatment of COVID-19-AKI, based on current literature data. It also proposes directions for future clinical research to expand understanding of the mechanisms of kidney damage in novel coronavirus infection and improve the outcomes of COVID-19 AKI.
This publication is an unchanged translation of the ADQI guidelines for COVID-19 associated acute kidney injury. The work carried out is intended to increase the availability of the expert document among a larger number of clinicians specializing in nephrology, internal medicine and intensive care and is of great practical importance in a pandemic.

Keywords: acute kidney injury associated with COVID-19, COVID-19AKI, renal replacement therapy, extracorporeal blood purification